Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):333-338
Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China,E-mail:
Objective: To study the efficacy and safety of continuous intravenous infusion of 2-Chlorodeoxyadenosine (2-CdA) combined with high-dose cytarabine (Ara-C) and granulocyte colony-stimulating factor (G-CSF) (CLAG regiem) in the treatment of relapsed/refractory acute myeloid leukemia (AML).
Methods: Fifteen patients with refractory/relapsed AML hospitalized in 5 medical units such as Department of Hematology, the Affiliated Tumor Hospital of Zhengzhou University and received one course of CLAG regimen from June 2014 to August 2019 were analyzed retrospectively (specifically: cladribine 5 mg/M, day 1 to day 5, continuous 24-hour intravenous infusion; Ara-C 2 g/M, 1 time/day, day 1 to day 5, intravenous infusion; G-CSF 300 mg, 1 time/day, day 0 to day 5, subcutaneous injection).
Results: Among the 15 patients with refractory/relapsed AML, 9 males and 6 females, the median age was 35 (13-63) years old. Read More